Welcome to our dedicated page for Bridgebio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BridgeBio Pharma, Inc. filings document a commercial-stage biopharmaceutical company focused on medicines for genetic conditions, including financial results, product revenue disclosures, program updates, and formal reports on ATTR-CM, LGMD2I/R9, and achondroplasia development programs.
Its SEC record includes Form 8-K disclosures for results of operations, Regulation FD presentations, clinical and regulatory press releases, material agreements, an at-the-market equity distribution agreement, convertible senior notes, and a board-authorized stock repurchase program. Proxy materials address director elections, executive compensation votes, auditor ratification, incentive plan share reserves, governance structure, and stockholder voting matters.
BridgeBio Pharma (NASDAQ: BBIO) filed a Form 4 disclosing that director Frank P. McCormick sold 100,000 common shares on 06/24/2025 under a pre-arranged Rule 10b5-1 plan.
The shares were sold at a weighted-average price of $44.23, generating proceeds of roughly $4.4 million.
Following the sale, McCormick owns 879,979 shares indirectly through his revocable trust and 83,275 shares directly, implying the transaction reduced his total position by about 9-10%.
No derivative securities were involved and no other insiders were party to the filing.
BridgeBio Pharma Form 144 Notice filed on June 28, 2025, details a proposed sale of securities by Denis Von Kaeppler IRA Rollover, who is related to the company through their wife's Board of Directors position.
Key transaction details:
- Securities to be sold: 1,891 shares of common stock
- Aggregate market value: $83,261.30
- Planned sale date: June 26, 2025 on NASDAQ
- Broker: Morgan Stanley Smith Barney LLC
The shares were originally acquired through an open market purchase on December 28, 2021. Notable recent insider activity includes multiple sales by Hannah Valantine, who sold a total of 17,168 shares for approximately $686,334 in gross proceeds on June 10, 2025. The company has approximately 189.9 million shares outstanding.
BridgeBio Pharma, Inc. (BBIO) – Form 144 filing dated 26 June 2025 discloses a proposed Rule 144 sale by Hannah Valantine & Denis von Kaeppler, who are identified as the spouse and joint owner of a member of the Board of Directors. The filing covers 1,542 common shares to be sold through Morgan Stanley Smith Barney on or about 26 June 2025 on Nasdaq, carrying an aggregate market value of $67,863.42. With 189,880,720 shares outstanding, the planned sale represents roughly 0.0008 % of shares outstanding.
The form also reports insider activity over the prior three months: four separate sales dated 10 June 2025, each involving 4,292 shares at gross proceeds of roughly $171.6 k apiece, totalling 17,168 shares and ~$686 k. All securities were originally acquired on 28 Dec 2021 via an open-market purchase paid in cash.
No adverse non-public information is acknowledged, and the signatory affirms compliance with Rule 144 representations. From a capital-markets perspective, the volumes involved are immaterial relative to BridgeBio’s float and should not affect liquidity or ownership structure in a meaningful way. Nevertheless, continued insider selling—even in small lots—can be interpreted by some investors as a sentiment cue and merits monitoring alongside future insider transaction patterns.